{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,8,25]],"date-time":"2026-08-25T01:13:27Z","timestamp":1787620407746,"version":"build-2736575974"},"reference-count":67,"publisher":"Elsevier BV","issue":"3","license":[{"start":{"date-parts":[[2008,6,1]],"date-time":"2008-06-01T00:00:00Z","timestamp":1212278400000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"}],"content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":["The Veterinary Journal"],"published-print":{"date-parts":[[2008,6]]},"DOI":"10.1016\/j.tvjl.2007.03.002","type":"journal-article","created":{"date-parts":[[2007,5,1]],"date-time":"2007-05-01T11:10:51Z","timestamp":1178017851000},"page":"310-319","source":"Crossref","is-referenced-by-count":90,"title":["The efficacy and tolerability of levetiracetam in pharmacoresistant epileptic dogs"],"prefix":"10.1016","volume":"176","author":[{"given":"Holger A.","family":"Volk","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Lara A.","family":"Matiasek","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Alejandro","family":"Luj\u00e1n Feliu-Pascual","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Simon R.","family":"Platt","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Kate E.","family":"Chandler","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"key":"10.1016\/j.tvjl.2007.03.002_bib1","doi-asserted-by":"crossref","first-page":"139","DOI":"10.1016\/j.seizure.2004.12.006","article-title":"Clinical experience of levetiracetam monotherapy for adults with epilepsy: 1-year follow-up study","volume":"14","author":"Alsaadi","year":"2005","journal-title":"Seizure-European Journal of Epilepsy"},{"key":"10.1016\/j.tvjl.2007.03.002_bib2","doi-asserted-by":"crossref","first-page":"618","DOI":"10.1016\/S1474-4422(04)00882-8","article-title":"Efficacy and tolerability of the new antiepileptic drugs: comparison of two recent guidelines","volume":"3","author":"Beghi","year":"2004","journal-title":"Lancet Neurology"},{"key":"10.1016\/j.tvjl.2007.03.002_bib3","doi-asserted-by":"crossref","first-page":"57","DOI":"10.1016\/S0920-1211(02)00247-4","article-title":"Evidence for sustained efficacy of levetiracetam as add-on epilepsy therapy","volume":"53","author":"Ben Menachem","year":"2003","journal-title":"Epilepsy Research"},{"key":"10.1016\/j.tvjl.2007.03.002_bib4","doi-asserted-by":"crossref","first-page":"281","DOI":"10.1080\/0049825042000196749","article-title":"Comparative pharmacokinetics and metabolism of levetiracetam, a new anti-epileptic agent, in mouse, rat, rabbit and dog","volume":"34","author":"Benedetti","year":"2004","journal-title":"Xenobiotica"},{"key":"10.1016\/j.tvjl.2007.03.002_bib5","unstructured":"Berendt, M., 2004. Epilepsy. In: Vite, C.H. (Ed.), Braund\u2019s Clinical Neurology in Small Animals: Localization, Diagnosis and Treatment, International Veterinary Information Service, Ithaca, NY, USA (www.ivis.org), July 2004. http:\/\/www.ivis.org\/advances\/Vite\/berendt\/chapter_frm.asp?LA=1 (accessed 10 October 2006)."},{"key":"10.1016\/j.tvjl.2007.03.002_bib6","doi-asserted-by":"crossref","first-page":"14","DOI":"10.1111\/j.1939-1676.1999.tb02159.x","article-title":"Epilepsy and seizure classification in 63 dogs: a reappraisal of veterinary epilepsy terminology","volume":"13","author":"Berendt","year":"1999","journal-title":"Journal of Veterinary Internal Medicine"},{"key":"10.1016\/j.tvjl.2007.03.002_bib7","first-page":"222","article-title":"Analysis of the \u201choneymoon effect\u201d in adult epilepsy patients","volume":"41","author":"Boggs","year":"2000","journal-title":"Epilepsia"},{"key":"10.1016\/j.tvjl.2007.03.002_bib8","doi-asserted-by":"crossref","first-page":"415","DOI":"10.1517\/14740338.3.5.415","article-title":"Levetiracetam safety profiles and tolerability in epilepsy patients","volume":"3","author":"Briggs","year":"2004","journal-title":"Expert Opinion on Drug Safety"},{"key":"10.1016\/j.tvjl.2007.03.002_bib9","doi-asserted-by":"crossref","unstructured":"Brodie, M.G., Perucca, E., Ryvlin, P., Ben-Menachem, E., Meencke, H.J., 2007. Levetiracetam Monotherapy Study Group. Comparison of levetiracetam and controlled-release carbamazepine in newly diagnosed epilepsy. Neurology 68, 402\u2013408.","DOI":"10.1212\/01.wnl.0000252941.50833.4a"},{"key":"10.1016\/j.tvjl.2007.03.002_bib10","doi-asserted-by":"crossref","first-page":"207","DOI":"10.1016\/j.tvjl.2005.07.001","article-title":"Canine epilepsy: what can we learn from human seizure disorders?","volume":"172","author":"Chandler","year":"2006","journal-title":"The Veterinary Journal"},{"key":"10.1016\/j.tvjl.2007.03.002_bib11","doi-asserted-by":"crossref","first-page":"590","DOI":"10.1111\/j.1528-1157.1999.tb05561.x","article-title":"New antiepileptic drugs: comparison of key clinical trials","volume":"40","author":"Cramer","year":"1999","journal-title":"Epilepsia"},{"key":"10.1016\/j.tvjl.2007.03.002_bib12","doi-asserted-by":"crossref","first-page":"15268","DOI":"10.1073\/pnas.96.26.15268","article-title":"Abnormal neurotransmission in mice lacking synaptic vesicle protein 2A (SV2A)","volume":"96","author":"Crowder","year":"1999","journal-title":"Proceedings of the National Academy of Sciences of the United States of America"},{"key":"10.1016\/j.tvjl.2007.03.002_bib13","first-page":"174","article-title":"Efficacy and safety of felbamate as an anticonvulsant in dogs with refractory seizures","volume":"10","author":"Dayrell-Hart","year":"1996","journal-title":"Journal of Veterinary Internal Medicine"},{"key":"10.1016\/j.tvjl.2007.03.002_bib14","doi-asserted-by":"crossref","first-page":"1107","DOI":"10.1016\/j.cvsm.2006.05.005","article-title":"Anticonvulsant therapy in dogs and cats","volume":"36","author":"Dewey","year":"2006","journal-title":"The Veterinary Clinics of North America. Small Animal Practice"},{"key":"10.1016\/j.tvjl.2007.03.002_bib15","doi-asserted-by":"crossref","first-page":"285","DOI":"10.5326\/0400285","article-title":"Zonisamide therapy for refractory idiopathic epilepsy in dogs","volume":"40","author":"Dewey","year":"2004","journal-title":"Journal of the American Animal Hospital Association"},{"key":"10.1016\/j.tvjl.2007.03.002_bib16","doi-asserted-by":"crossref","first-page":"161","DOI":"10.1016\/S0920-1211(98)00104-1","article-title":"Blood and cerebrospinal fluid pharmacokinetics of the novel anticonvulsant levetiracetam (ucb L059) in the rat","volume":"34","author":"Doheny","year":"1999","journal-title":"Epilepsy Research"},{"key":"10.1016\/j.tvjl.2007.03.002_bib17","doi-asserted-by":"crossref","first-page":"1304","DOI":"10.1111\/j.1528-1167.2005.04005.x","article-title":"Fast and sustained efficacy of levetiracetam during titration and the first 3 months of treatment in refractory epilepsy","volume":"46","author":"French","year":"2005","journal-title":"Epilepsia"},{"key":"10.1016\/j.tvjl.2007.03.002_bib18","doi-asserted-by":"crossref","first-page":"1252","DOI":"10.1212\/01.WNL.0000123693.82339.FC","volume":"62","author":"French","year":"2004","journal-title":"Neurology"},{"key":"10.1016\/j.tvjl.2007.03.002_bib19","doi-asserted-by":"crossref","first-page":"1261","DOI":"10.1212\/01.WNL.0000123695.22623.32","volume":"62","author":"French","year":"2004","journal-title":"Neurology"},{"key":"10.1016\/j.tvjl.2007.03.002_bib20","doi-asserted-by":"crossref","first-page":"11","DOI":"10.1016\/j.ejphar.2003.08.033","article-title":"Localization and photoaffinity labelling of the levetiracetam binding site in rat brain and certain cell lines","volume":"478","author":"Fuks","year":"2003","journal-title":"European Journal of Pharmacology"},{"key":"10.1016\/j.tvjl.2007.03.002_bib21","doi-asserted-by":"crossref","first-page":"102","DOI":"10.1016\/j.ejphar.2006.02.022","article-title":"Binding characteristics of levetiracetam to synaptic vesicle protein 2A (SV2A) in human brain and in CHO cells expressing the human recombinant protein","volume":"536","author":"Gillard","year":"2006","journal-title":"European Journal of Pharmacology"},{"key":"10.1016\/j.tvjl.2007.03.002_bib22","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1016\/j.ejphar.2003.08.032","article-title":"Binding characteristics of [3H]ucb 30889 to levetiracetam binding sites in rat brain","volume":"478","author":"Gillard","year":"2003","journal-title":"European Journal of Pharmacology"},{"key":"10.1016\/j.tvjl.2007.03.002_bib23","doi-asserted-by":"crossref","first-page":"350","DOI":"10.1046\/j.1528-1157.2002.18101.x","article-title":"Effects of the novel antiepileptic drug levetiracetam on spontaneous recurrent seizures in the rat pilocarpine model of temporal lobe epilepsy","volume":"43","author":"Glien","year":"2002","journal-title":"Epilepsia"},{"key":"10.1016\/j.tvjl.2007.03.002_bib24","doi-asserted-by":"crossref","first-page":"602","DOI":"10.1111\/j.1751-0813.2005.tb13269.x","article-title":"Improving seizure control in dogs with refractory epilepsy using gabapentin as an adjunctive agent","volume":"83","author":"Govendir","year":"2005","journal-title":"Australian Veterinary Journal"},{"key":"10.1016\/j.tvjl.2007.03.002_bib25","doi-asserted-by":"crossref","first-page":"207","DOI":"10.1016\/0920-1211(95)00077-1","article-title":"Effects of levetiracetam, a novel antiepileptic drug, on convulsant activity in two genetic rat models of epilepsy","volume":"22","author":"Gower","year":"1995","journal-title":"Epilepsy Research"},{"key":"10.1016\/j.tvjl.2007.03.002_bib26","doi-asserted-by":"crossref","first-page":"248","DOI":"10.1016\/j.seizure.2005.02.004","article-title":"Efficacy and safety of levetiracetam: an add-on trial in children with refractory epilepsy","volume":"14","author":"Grosso","year":"2005","journal-title":"Seizure"},{"key":"10.1016\/j.tvjl.2007.03.002_bib27","doi-asserted-by":"crossref","first-page":"36","DOI":"10.1046\/j.1528-1157.2001.00008.x","article-title":"Safety profile of levetiracetam","volume":"42","author":"Harden","year":"2001","journal-title":"Epilepsia"},{"key":"10.1016\/j.tvjl.2007.03.002_bib28","unstructured":"Holt, G., Volk, H.A., Chandler, K., 2005. The use of a questionnaire to compare clinical characteristics and type of seizure occurring in 3 dog breeds with idiopathic epilepsy. In: Proceedings of 18th Annual European College of Veterinary Neurologist Symposium, Munich, Germany."},{"key":"10.1016\/j.tvjl.2007.03.002_bib29","doi-asserted-by":"crossref","first-page":"1375","DOI":"10.1592\/phco.21.17.1375.34432","article-title":"Levetiracetam: a novel antiepileptic drug","volume":"21","author":"Hovinga","year":"2001","journal-title":"Pharmacotherapy"},{"key":"10.1016\/j.tvjl.2007.03.002_bib30","doi-asserted-by":"crossref","first-page":"825","DOI":"10.1046\/j.1528-1157.2001.042007825.x","article-title":"Pharmacokinetics of levetiracetam and its enantiomer (R)-alpha-ethyl-2-oxo-pyrrolidine acetamide in dogs","volume":"42","author":"Isoherranen","year":"2001","journal-title":"Epilepsia"},{"key":"10.1016\/j.tvjl.2007.03.002_bib31","doi-asserted-by":"crossref","first-page":"347","DOI":"10.1097\/00007691-200306000-00016","article-title":"Therapeutic drug monitoring of the newer antiepileptic drugs","volume":"25","author":"Johannessen","year":"2003","journal-title":"Therapeutic Drug Monitoring"},{"key":"10.1016\/j.tvjl.2007.03.002_bib32","doi-asserted-by":"crossref","first-page":"13","DOI":"10.1046\/j.1528-1157.2001.00003.x","article-title":"Levetiracetam: the preclinical profile of a new class of antiepileptic drugs?","volume":"42","author":"Klitgaard","year":"2001","journal-title":"Epilepsia"},{"key":"10.1016\/j.tvjl.2007.03.002_bib33","doi-asserted-by":"crossref","first-page":"191","DOI":"10.1016\/S0014-2999(98)00410-5","article-title":"Evidence for a unique profile of levetiracetam in rodent models of seizures and epilepsy","volume":"353","author":"Klitgaard","year":"1998","journal-title":"European Journal of Pharmacology"},{"issue":"Supp. 1","key":"10.1016\/j.tvjl.2007.03.002_bib34","first-page":"S9","article-title":"Antiepileptogenesis, neuroprotection, and disease modification in the treatment of epilepsy: focus on levetiracetam","volume":"5","author":"Klitgaard","year":"2003","journal-title":"Epileptic Disorders"},{"key":"10.1016\/j.tvjl.2007.03.002_bib35","doi-asserted-by":"crossref","first-page":"1772","DOI":"10.1212\/WNL.56.12.1772","article-title":"Long-term continuation of levetiracetam in patients with refractory epilepsy","volume":"56","author":"Krakow","year":"2001","journal-title":"Neurology"},{"key":"10.1016\/j.tvjl.2007.03.002_bib36","doi-asserted-by":"crossref","first-page":"460","DOI":"10.1016\/S1525-5050(02)00523-1","article-title":"Clinical presentations of naturally occurring canine seizures: similarities to human seizures","volume":"3","author":"Licht","year":"2002","journal-title":"Epilepsy and Behavior"},{"key":"10.1016\/j.tvjl.2007.03.002_bib37","first-page":"574","article-title":"Pharmakologische Grundlagen zur Behandlung der Epilepsie bei Hund und Katze","volume":"8","author":"L\u00f6scher","year":"2003","journal-title":"Der Praktische Tierarzt"},{"key":"10.1016\/j.tvjl.2007.03.002_bib38","doi-asserted-by":"crossref","first-page":"147","DOI":"10.1016\/0014-2999(93)90768-D","article-title":"Profile of ucb L059, a novel anticonvulsant drug, in models of partial and generalized epilepsy in mice and rats","volume":"232","author":"L\u00f6scher","year":"1993","journal-title":"European Journal of Pharmacology"},{"key":"10.1016\/j.tvjl.2007.03.002_bib39","doi-asserted-by":"crossref","first-page":"474","DOI":"10.1016\/S0022-3565(24)37251-9","article-title":"Antiepileptogenic effects of the novel anticonvulsant levetiracetam (ucb L059) in the kindling model of temporal lobe epilepsy","volume":"284","author":"L\u00f6scher","year":"1998","journal-title":"Journal of Pharmacology and Experimental Therapeutics"},{"key":"10.1016\/j.tvjl.2007.03.002_bib40","doi-asserted-by":"crossref","first-page":"1253","DOI":"10.1111\/j.1528-1167.2006.00607.x","article-title":"Experimental and clinical evidence for loss of effect (tolerance) during prolonged treatment with antiepileptic drugs","volume":"47","author":"L\u00f6scher","year":"2006","journal-title":"Epilepsia"},{"key":"10.1016\/j.tvjl.2007.03.002_bib41","doi-asserted-by":"crossref","first-page":"9","DOI":"10.1046\/j.1528-1157.2002.24501.x","article-title":"Selective blockade of N-type calcium channels by levetiracetam","volume":"43","author":"Lukyanetz","year":"2002","journal-title":"Epilepsia"},{"key":"10.1016\/j.tvjl.2007.03.002_bib42","doi-asserted-by":"crossref","first-page":"9861","DOI":"10.1073\/pnas.0308208101","article-title":"The synaptic vesicle protein SV2A is the binding site for the antiepileptic drug levetiracetam","volume":"101","author":"Lynch","year":"2004","journal-title":"Proceedings of the National Academy of Sciences of the United States of America"},{"key":"10.1016\/j.tvjl.2007.03.002_bib43","doi-asserted-by":"crossref","first-page":"281","DOI":"10.1006\/phrs.2000.0689","article-title":"Inhibition of neuronal hypersynchrony in vitro differentiates levetiracetam from classical antiepileptic drugs","volume":"42","author":"Margineanu","year":"2000","journal-title":"Pharmacological Research"},{"key":"10.1016\/j.tvjl.2007.03.002_bib44","doi-asserted-by":"crossref","first-page":"255","DOI":"10.1016\/S0014-2999(03)01563-2","article-title":"Levetiracetam has no significant gamma-aminobutyric acid-related effect on paired-pulse interaction in the dentate gyrus of rats","volume":"466","author":"Margineanu","year":"2003","journal-title":"European Journal of Pharmacology"},{"key":"10.1016\/j.tvjl.2007.03.002_bib45","doi-asserted-by":"crossref","first-page":"1","DOI":"10.3310\/hta5310","article-title":"Design and use of questionnaires: a review of best practice applicable to surveys of health service staff and patients","volume":"5","author":"McColl","year":"2001","journal-title":"Health Technology Assessment"},{"key":"10.1016\/j.tvjl.2007.03.002_bib46","doi-asserted-by":"crossref","first-page":"5","DOI":"10.1016\/S0304-3940(01)01884-5","article-title":"Levetiracetam inhibits the high-voltage-activated Ca(2+) current in pyramidal neurones of rat hippocampal slices","volume":"306","author":"Niespodziany","year":"2001","journal-title":"Neuroscience Letters"},{"key":"10.1016\/j.tvjl.2007.03.002_bib47","doi-asserted-by":"crossref","first-page":"77","DOI":"10.1016\/S0163-7258(99)00052-2","article-title":"Pharmacokinetic profile of levetiracetam: toward ideal characteristics","volume":"85","author":"Patsalos","year":"2000","journal-title":"Pharmacology and Therapeutics"},{"key":"10.1016\/j.tvjl.2007.03.002_bib48","first-page":"881","article-title":"Gabapentin Therapy for Refractory Idiopathic Epilepsy in Dogs","volume":"159","author":"Platt","year":"2007","journal-title":"The Veterinary Record"},{"key":"10.1016\/j.tvjl.2007.03.002_bib49","doi-asserted-by":"crossref","first-page":"185","DOI":"10.1016\/S1096-2867(98)80040-6","article-title":"Antiepileptic drug therapy","volume":"13","author":"Podell","year":"1998","journal-title":"Clinical Techniques in Small Animal Practice"},{"key":"10.1016\/j.tvjl.2007.03.002_bib50","doi-asserted-by":"crossref","first-page":"318","DOI":"10.1111\/j.1939-1676.1993.tb01025.x","article-title":"Bromide therapy in refractory canine idiopathic epilepsy","volume":"7","author":"Podell","year":"1993","journal-title":"Journal of Veterinary Internal Medicine"},{"key":"10.1016\/j.tvjl.2007.03.002_bib51","doi-asserted-by":"crossref","first-page":"109","DOI":"10.1016\/S0920-1211(98)00106-5","article-title":"Clinical aspects and biological bases of drug-resistant epilepsies","volume":"34","author":"Regesta","year":"1999","journal-title":"Epilepsy Research"},{"key":"10.1016\/j.tvjl.2007.03.002_bib52","doi-asserted-by":"crossref","first-page":"952","DOI":"10.1016\/S0140-6736(83)90462-2","article-title":"Why Does Epilepsy Become Intractable - Prevention of Chronic Epilepsy","volume":"2","author":"Reynolds","year":"1983","journal-title":"Lancet"},{"key":"10.1016\/j.tvjl.2007.03.002_bib53","first-page":"91","article-title":"Wirkung verschiedener antiepileptischer Substanzen beim Hund","volume":"3","author":"Riek","year":"2002","journal-title":"Tier\u00e4rztliche Praxis"},{"key":"10.1016\/j.tvjl.2007.03.002_bib54","doi-asserted-by":"crossref","first-page":"659","DOI":"10.1038\/sj.bjp.0704766","article-title":"The anti-epileptic drug levetiracetam reverses the inhibition by negative allosteric modulators of neuronal","volume":"136","author":"Rigo","year":"2002","journal-title":"British Journal of Pharmacology"},{"key":"10.1016\/j.tvjl.2007.03.002_bib55","doi-asserted-by":"crossref","first-page":"553","DOI":"10.1038\/nrn1430","article-title":"The neurobiology of antiepileptic drugs","volume":"5","author":"Rogawski","year":"2004","journal-title":"Nature reviews. Neuroscience"},{"key":"10.1016\/j.tvjl.2007.03.002_bib56","first-page":"94","article-title":"Is levetiracetam distinct from conventional antiepileptic drugs in antiepileptogenic properties in spontaneous epileptic rats?","volume":"46","author":"Sasa","year":"2005","journal-title":"Epilepsia"},{"key":"10.1016\/j.tvjl.2007.03.002_bib57","doi-asserted-by":"crossref","first-page":"113","DOI":"10.1111\/j.1365-2885.1985.tb00934.x","article-title":"Therapeutic efficacy of phenobarbital and primidone in canine epilepsy: a comparison","volume":"8","author":"Schwartz-Porsche","year":"1985","journal-title":"Journal of Veterinary Pharmacology and Therapeutics"},{"key":"10.1016\/j.tvjl.2007.03.002_bib58","doi-asserted-by":"crossref","first-page":"149","DOI":"10.1016\/S0014-2999(02)02235-5","article-title":"Lack of effects of prolonged treatment with phenobarbital or phenytoin on the expression of P-glycoprotein in various rat brain regions","volume":"451","author":"Seegers","year":"2002","journal-title":"European Journal of Pharmacology"},{"key":"10.1016\/j.tvjl.2007.03.002_bib59","doi-asserted-by":"crossref","first-page":"35","DOI":"10.1016\/S0014-2999(97)00105-2","article-title":"Neurochemical studies with the novel anticonvulsant levetiracetam in mouse brain","volume":"325","author":"Sills","year":"1997","journal-title":"European Journal of Pharmacology"},{"key":"10.1016\/j.tvjl.2007.03.002_bib60","unstructured":"Steinberg, M., Faissler, D., 2004. Levetiracetam therapy for longterm idiopathic epileptic dogs. In: Proceedings of the 22nd Annual American College of Veterinary Internal Medicine Forum."},{"key":"10.1016\/j.tvjl.2007.03.002_bib61","doi-asserted-by":"crossref","first-page":"867","DOI":"10.1038\/sj.bjp.0704141","article-title":"A microdialysis study of the novel antiepileptic drug levetiracetam: extracellular pharmacokinetics and effect on taurine in rat brain","volume":"133","author":"Tong","year":"2001","journal-title":"British Journal of Pharmacology"},{"key":"10.1016\/j.tvjl.2007.03.002_bib62","doi-asserted-by":"crossref","first-page":"1449","DOI":"10.2460\/javma.1998.213.10.1449","article-title":"Therapeutic serum drug concentrations in epileptic dogs treated with potassium bromide alone or in combination with other anticonvulsants: 122 cases (1992\u20131996)","volume":"213","author":"Trepanier","year":"1998","journal-title":"Journal of the American Veterinary Medical Association"},{"key":"10.1016\/j.tvjl.2007.03.002_bib63","unstructured":"Von Klopmann, T., Simon, D., Tipold, A., 2005. Zonisamide add-on therapy for canine refractory epilepsy: Benefit or \u201cHoney -Moon Effect\u201d. In: Proceedings of 18th Annual European College of Veterinary Neurologist Symposium, Munich, Germany."},{"key":"10.1016\/j.tvjl.2007.03.002_bib64","doi-asserted-by":"crossref","first-page":"282","DOI":"10.1046\/j.1528-1157.2001.4220282.x","article-title":"ILAE Commission Report. Proposal for a new classification of outcome with respect to epileptic seizures following epilepsy surgery","volume":"42","author":"Wieser","year":"2001","journal-title":"Epilepsia"},{"key":"10.1016\/j.tvjl.2007.03.002_bib65","doi-asserted-by":"crossref","first-page":"1","DOI":"10.3310\/hta9150","article-title":"Clinical effectiveness, tolerability and cost-effectiveness of newer drugs for epilepsy in adults: a systematic review and economic evaluation","volume":"9","author":"Wilby","year":"2005","journal-title":"Health Technology Assessment"},{"key":"10.1016\/j.tvjl.2007.03.002_bib66","doi-asserted-by":"crossref","first-page":"1170","DOI":"10.1111\/j.1528-1167.2005.35204.x","article-title":"Separation of antiepileptogenic and antiseizure effects of levetiracetam in the spontaneously epileptic rat (SER)","volume":"46","author":"Yan","year":"2005","journal-title":"Epilepsia"},{"key":"10.1016\/j.tvjl.2007.03.002_bib67","doi-asserted-by":"crossref","first-page":"279","DOI":"10.1053\/seiz.2000.0504","article-title":"Levetiracetam does not modulate neuronal voltage-gated Na+ and T-type Ca2+ currents","volume":"10","author":"Zona","year":"2001","journal-title":"Seizure"}],"container-title":["The Veterinary Journal"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S1090023307001025?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S1090023307001025?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2025,1,16]],"date-time":"2025-01-16T00:12:12Z","timestamp":1736986332000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S1090023307001025"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2008,6]]},"references-count":67,"journal-issue":{"issue":"3","published-print":{"date-parts":[[2008,6]]}},"alternative-id":["S1090023307001025"],"URL":"https:\/\/doi.org\/10.1016\/j.tvjl.2007.03.002","relation":{},"ISSN":["1090-0233"],"issn-type":[{"value":"1090-0233","type":"print"}],"subject":[],"published":{"date-parts":[[2008,6]]}}}